Compare Nuwellis Inc (NUWE) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs ProShares Ultra Gold ETF — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while ProShares Ultra Gold ETF trades at $46.5 (market cap $715.43M). The key difference: ProShares Ultra Gold ETF is far larger — about 325.2× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 3,002,043). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and ProShares Ultra Gold ETF for 23 Days on average.
| NUWE | UGL | |
|---|---|---|
Market Cap | $2.20M | $715.43M |
Volume | 121,544 | 3,002,043 |
Sector | Health | Leveraged / Inverse |
52-Week High | $146.65 | $85.62 |
52-Week Low | $0.68 | $42.79 |
Typical Hold Time | 26 Days | 23 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
UGL stock is trading at $44.43, down 3.29% over the past day amid a broader bearish technical signal. The stock faces selling pressure with moving averages and oscillators indicating a downtrend, while key support lies at $43. Recent news highlights gold's volatility driven by shifting Federal Reserve rate expectations and Treasury yield movements, impacting sentiment.
The outlook remains cautious with technical indicators signaling bearish momentum, though oversold conditions on the 12-day RSI may offer short-term relief. Risks include persistent macroeconomic headwinds from interest rates and dollar strength, while the lack of available fundamental data limits visibility on the company's financial health and valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
